Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Survival and clinical response to bortezomib, thalidomide, and dexamethasone in patients with multiple myeloma at a peruvian tertiary care center: A real-world retrospective observational study

View Full Paper
Ask AI
Bookmark
Share

Authors

BAB. Alegre

Discussion

Loading...

Member takes

Overview

Observational study shows VTD improves response rates in multiple myeloma, indicating ASCT may enhance overall survival.

Key Points

  • To evaluate treatment responses and survival outcomes of multiple myeloma patients receiving the VTD regimen in Peru.
  • Retrospective observational study at a tertiary care center
  • Included adult patients with multiple myeloma treated with VTD
  • Responses assessed per International Myeloma Working Group criteria
  • Progression-free survival and overall survival estimated using Kaplan–Meier method
  • Median progression-free survival was 46 months
  • Complete response achieved in 21.1% of patients
  • Chronic kidney disease present in 10.5% of patients
  • Autologous stem cell transplantation significantly reduced risk of death by 82%

Cite This Study

B. Alegre (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1dahttps://doi.org/10.1182/blood-2025-7518
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients2024 · 1 citations
  2. 2P25 | REAL-WORLD OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA: EVIDENCE SUPPORTING BORTEZOMIB–LENALIDOMIDE–DEXAMETHASONE AS A PREFERRED REGIMEN WITHOUT ANTI-CD38 ANTIBODIES2026
  3. 3Real-World Outcomes in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma Treated With Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Lenalidomide/Dexamethasone as Upfront Treatment2024
  4. 4Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study2025
  5. 5Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation2024